CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...

(Reuters) - President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from ...

AstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

On the heels of a new Food and Drug Administration approval for its billion-dollar drug Xgeva, Amgen announced that the European Medicines Agency would consider an application for osteoporosis drug ...

Amgen’s Kyprolis (carfilzomib) has been granted an expanded label in Europe, to include use with dexamethasone alone in adults with multiple myeloma who have received at least on prior therapy.

Rory McIlroy looking to secure career Grand Slam in 2025 by winning The Masters at Augusta National and claiming elusive fifth major; McIlroy will feature in Europes Ryder Cup team at Bethpage Black; ...